tetano
Editor, Senior Moderator
CEN Case Rep
. 2022 Jan 7.
doi: 10.1007/s13730-021-00681-z. Online ahead of print.
Influenza-induced thrombotic microangiopathy in a patient with cancer on proteasome inhibitor: a diagnostic dilemma
Christopher D Hamad[SUP] 1 [/SUP], Zachary C Hoelscher[SUP] 1 [/SUP], Amanda Tchakarov[SUP] 2 [/SUP], Jaya Kala[SUP] 3 [/SUP]
Affiliations
Abstract
Thrombotic microangiopathy (TMA) in a cancer patient is a common complication of either cancer itself or anticancer therapy. Incidence of TMA from anticancer therapy was found to be > 15%, since the introduction of anti-angiogenic drugs like anti-vascular endothelial growth factor agents. It is, however, important to not ignore other causes of TMA such as bacteria, viruses, antiplatelet drugs, hereditary complement mutations, and autoimmune disorders. We present such a diagnostic dilemma in our patient who was admitted with influenza and was found to have TMA on renal biopsy, while on proteasome inhibitor (PI) therapy. With this case, we would like to highlight the importance of understanding the true cause of TMA to avoid unwarranted long-term discontinuation of life saving anti-cancer drugs after TMA resolution.
Keywords: Cancer chemotherapy-induced kidney injury; Influenza virus; Proteasome inhibitor; Thrombotic microangiopathy.
. 2022 Jan 7.
doi: 10.1007/s13730-021-00681-z. Online ahead of print.
Influenza-induced thrombotic microangiopathy in a patient with cancer on proteasome inhibitor: a diagnostic dilemma
Christopher D Hamad[SUP] 1 [/SUP], Zachary C Hoelscher[SUP] 1 [/SUP], Amanda Tchakarov[SUP] 2 [/SUP], Jaya Kala[SUP] 3 [/SUP]
Affiliations
- PMID: 34997535
- DOI: 10.1007/s13730-021-00681-z
Abstract
Thrombotic microangiopathy (TMA) in a cancer patient is a common complication of either cancer itself or anticancer therapy. Incidence of TMA from anticancer therapy was found to be > 15%, since the introduction of anti-angiogenic drugs like anti-vascular endothelial growth factor agents. It is, however, important to not ignore other causes of TMA such as bacteria, viruses, antiplatelet drugs, hereditary complement mutations, and autoimmune disorders. We present such a diagnostic dilemma in our patient who was admitted with influenza and was found to have TMA on renal biopsy, while on proteasome inhibitor (PI) therapy. With this case, we would like to highlight the importance of understanding the true cause of TMA to avoid unwarranted long-term discontinuation of life saving anti-cancer drugs after TMA resolution.
Keywords: Cancer chemotherapy-induced kidney injury; Influenza virus; Proteasome inhibitor; Thrombotic microangiopathy.